Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.

Author(s)
Onomoto, Koji; Morimoto, Shiho; Kawaguchi, Takahisa; Toyoda, Hidenori; Tanaka, Masami; Kuroda, Masahiko; Uno, Kazuko; Kumada, Takashi; Matsuda, Fumihiko; Shimotohno, Kunitada; Fujita, Takashi; Murakami, Yoshiki

Citation
PloS one (2011), 6(5)

Issue Date
2011

URL
http://hdl.handle.net/2433/141816

Right
© 2011 Onomoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Type
Journal Article
Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C

Koji Onomoto1,7*, Shiho Morimoto1, Takahisa Kawaguchi2, Hidenori Toyoda3, Masami Tanaka4, Masahiko Kuroda4, Kazuko Uno5, Takashi Kumada3, Fumihiko Matsuda2, Kunitada Shimotohno6, Takashi Fujita1, Yoshiki Murakami2*

1 Institute for Viral Research and Graduate School of Bioscience, Kyoto University, Kyoto, Japan, 2 Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3 Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan, 4 Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan, 5 Louis Pasteur Center for Medical Research, Kyoto, Kyoto, Japan, 6 Research Institute, Chiba Institute for Technology, Narashino, Japan, 7 Research Institute for Science and Engineering, Waseda University, Tokyo, Japan

Abstract

Background: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)-α and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. This makes it necessary to predict patient outcome so as to improve the accuracy of treatment. Although the antiviral mechanism of genetically altered IL28B is unknown, IL28B polymorphism is considered a good predictor of IFN combination treatment outcome.

Methodology: Using microarray, we quantified the expression profile of 237 IFN related genes in 87 CH liver biopsy specimens to clarify the relationship between IFN pathway and viral elimination, and to predict patients’ clinical outcome. In 72 out of 87 patients we also analyzed IL28B polymorphism (rs8099917).

Principal Findings: Five IFN related-genes (IFI27, IFI 44, ISG15, MX1, and OAS1) had expression levels significantly higher in nonresponders (NR) than in normal liver (NL) and sustained virological responders (SVR); this high expression was also frequently seen in cases with the minor (TG or GG) IL28B genotype. The expression pattern of 31 IFN related-genes also differed significantly between NR and NL. We predicted drug response in NR with 86.1% accuracy by diagonal linear discriminant analysis (DLDA).

Conclusion: IFN system dysregulation before treatment was associated with poor IFN therapy response. Determining IFN related-gene expression pattern based on patients’ response to combination therapy, allowed us to predict drug response with high accuracy. This method can be applied to establishing novel antiviral therapies and strategies for patients using a more individual approach.

Introduction

Hepatitis C virus (HCV) infection affects more than 3% of the world population. Without suitable treatment, chronic hepatitis C (CH) frequently leads to the development of chronic liver diseases such as liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [1]. The current standard treatment for CH is a combination of pegylated-IFN (Peg-IFN)-α and ribavirin (hereafter CH combination therapy). Over a 15-year observation period, the rate of hepatocarcinogenesis was found to be significantly lower in sustained viral responders (SVR) and relapse (R) patients than in non responders (NR) and interferon (IFN) untreated patients [2]. However, CH combination therapy achieves a sustained virological response in 50–55% of patients with HCV genotype 1b infection [3]. Consequently, this creates a pressing need to develop alternative strategies for treating CH.

IFN Type-I and III play various important immunomodulatory roles in both innate immune and acquired immune responses. Four main effector pathways of the IFN-mediated antiviral response have been recognized by gene targeting studies: the Mx GTPase pathway, the 2-5′-oligoaadenylate-synthetase-directed ribonuclease L (OASL) pathway, the protein kinase R (PKR) pathway and the interferon stimulated gene (ISG) 15 ubiquitin-like pathway. These effector-pathways individually block viral...
transcription, degrade viral RNA, inhibit translation and modify protein function to control all steps of viral replication [4–5]. IFN treatment for CH usually results in a high incidence of side effects; therefore, it is important to adjust IFN treatment accurately using a prediction method. Viral factors (HCV genotype, pretreatment viral load, and sequence of HCV gene core and NS5A), [6–7] host factors (obesity, cirrhosis, ethnic background, serum cytokine levels, liver fibrosis grades) [8], and treatment factors (adequate course of treatment, adherence to the treatment, management of side effects) [9] has been utilized in prior research to predict the outcome of combination therapy. Hepatic microRNA expression pattern before anti-viral treatment has also been utilized as a prediction biomarker of drug response in CH [10], while other studies have shown that there is a possible association between two SNPs near the gene interleukin 28B (IL28B) on chromosome 19 and lack of response to combination therapy [11–13].

In this study, we evaluated the IFN related gene expression profiles in CH patients before administering CH combination treatment. After the anti-viral therapy, patients were classified according to their clinical outcome: sustained viral response (SVR), relapse (R), and non responder (NR). It was observed that in the NR group, the expression level of some IFN related genes was significantly higher than that in normal liver (NL) groups, and that the expression level of the other IFN related genes was significantly lower than in NL. Moreover, the significantly high expression of IFN related genes was associated with low response to combination therapy. This suggests that dysregulation of the IFN system can be related to cases of CH combination therapy failure.

Results

In order to provide specific information with less data analysis, we developed a custom-made focused DNA microarray called Genopal (Mitsubishi Rayon, Tokyo, Japan) using genes that target human innate-immunity. Based on the results from the expression profiles, we carefully selected 237 gene probes (materials and methods) by activating RIG-I with Agilent DNA microarray. A microarray platform was used to establish IFN-related gene expression profiles in the specimens collected from the 87 CH and 5 NL samples (Table 1). The results of the analysis of these genes using the DNA chip strongly correlated with those obtained by real-time PCR (Pearson’s correlation coefficient R2 = 0.996, P<0.0001; data not shown).

| Table 1. Clinical characteristics of patients. |
|-----------------------------------------------|
| Characteristics                                      |
| SVR (n = 38) | R (n = 26) | NR (n = 23) | NL (n = 5) |
| Age (yrs) | 56.7±10.3 | 61.3±8.6 | 60.8±7.8 | 57.2±9.5 |
| Male (%) | 28 (61%) | 11 (39%) | 9 (36%) | 3 (60%) |
| Weight (kg) | 59.5±8.9 | 57.2±10.3 | 55.7±7.2 | ND |
| HCV RNA (x10^4 copies/ml) | 2.00±2.07 | 1.79±1.02 | 1.55±0.95 | ND |
| Fibrosis stage | |
| F0 | 1 | 1 | 1 |
| F1 | 29 | 13 | 10 |
| F2 | 9 | 7 | 5 |
| F3 | 6 | 4 | 6 |
| F4 | 0 | 0 | 1 |
| WBC (<10^3/mm^3) | 5.42±1.63 | 5.23±1.25 | 4.69±1.13 | ND |
| Hemoglobin (g/dl) | 14.3±1.14 | 13.5±1.35 | 13.6±1.09 | ND |
| Platelet (<10^5/mm^3) | 16.7±5.3 | 16.6±4.0 | 15.0±5.7 | ND |
| AST (IU/L) | 59.2±51.0 | 48.7±30.1 | 57.4±29.7 | ND |
| ALT (IU/L) | 80.8±93.7 | 49.3±29.6 | 69.1±44.4 | ND |
| γGTP (IU/L) | 60.3±74.2 | 41.2±29.7 | 76.2±60.2 | ND |
| ALP (IU/L) | 255±74.0 | 246±71.3 | 314±144 | ND |
| Total bilirubin (mg/dl) | 0.66±0.22 | 0.73±0.31 | 0.69±0.19 | ND |
| Albumin (g/dl) | 4.20±0.34 | 4.14±0.25 | 4.02±0.48 | ND |

In this study, we evaluated the IFN related gene expression profiles in CH patients before administering CH combination treatment. After the anti-viral therapy, patients were classified according to their clinical outcome: sustained viral response (SVR), relapse (R), and non responder (NR). It was observed that in the NR group, the expression level of some IFN related genes was significantly higher than that in normal liver (NL) groups, and that the expression level of the other IFN related genes was significantly lower than in NL. Moreover, the significantly high expression of IFN related genes was associated with low response to combination therapy. This suggests that dysregulation of the IFN system can be related to cases of CH combination therapy failure.

IFN related genes associated with the final response to combination therapy

We determined unique IFN gene expression patterns for liver specimens with or without HCV based on the final virological response to the combination therapy. The expression level of 66 genes significantly differed among NR, R, SVR, and normal liver (NL) groups (Figure 1). To clearly identify the IFN-related genes associated with the clinical outcome, we extracted genes that showed significant differences (p<0.05). It was observed that the expression level of 5 genes (myxovirus (influenza virus) resistance 1 (MX1), 2',5'-oligoadenylate synthetase 1 (OAS1), ISG15 ubiquitin-like modifier (ISG15), interferon, alpha-inducible protein 27 (IFI27), and interferon, alpha-inducible protein 44 (IFI44)) were significantly higher in NR than in SVR samples (Table 2). The expression levels of 3 genes (MX1, IFI27, and ISG15) were significantly higher in NR than in R samples (Table 2). We also analyzed the IFN-related gene expression pattern according to the grade of inflammation or stage of fibrosis, however, no significant differences was observed between the two (data not shown).

Comparison of IFN related genes between CH and NL

We also compared the gene expression pattern in NR and NL. After extracting genes with a fold change <1/3, 5< and p-value<0.05, we found that the expression level of 6 genes (growth arrest and DNA-damage-inducible, beta (GADD45B), hairy and enhancer of split 2 (HES2), signal transducer and activator of transcription 3 (STAT3), suppressor of cytokine signaling 3 (SOCS3), and DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (DDX11)) was significantly lower in NR than in NL. The expression level of SOCS3 and DDX11 in NR was significantly lower than in SVR. The expression level of 25 genes were significantly higher in NR than in NL. The expression levels of most of these genes were significantly higher in NR than in SVR, but the expression level of tumor necrosis factor (ligand) superfamily, member 10 (TRAIL), major histocompatibility complex, class I, C (HLA-C), major histocompatibility complex, class I, B (HLA-B), and chemokine (C-X-C motif) ligand 10 (CXCL10) (IP10) were similar in NR and SVR samples (Table 3).

Validation of the microarray result by real-time qPCR

The five genes (ISG15, MX1, OAS1, IFI27 and IFI44) with the largest difference in fold change between NR and SVR groups were chosen to confirm the microarray results using real-time qPCR (Figure 2).
qPCR. The result from real-time qPCR supported the results from the microarray analysis (Figure S1).

**Prediction of the clinical outcome by DLDA**

We attempted to simulate the clinical outcome of the CH combination therapy using diagonal linear discriminant analysis (DLDA). Patients were randomly divided into TS (training set) and VS (validation set) (Table 4) in the order in which their samples were obtained. Samples within each group were then classified as NR or non-NR (SVR+R). DLDA showed that the accuracy, sensitivity, specificity, positive and negative predictive value of these two classifications were 86.1%, 87.5%, 81.8%, 93.3%, and 93.3%. 

**Figure 1. Clustering of IFN related gene expression.** Clustering of CH patients according to the expression profiles of the 66 genes that showed significant differences among SVR, R, NR, and NL. Vertical bars represent the IFN related genes and the horizontal bars represent the samples. Green bars reflect down-regulated genes and red bars up-regulated genes.

doi:10.1371/journal.pone.0019799.g001
expression of IFN related genes

Genetic variation of IL28B is correlated with the expression of IFN related gene and IL28B polymorphism showed that the accuracy with which patients were classified as SVR, R, and NR was 56.8% and as SVR, R, and NR was 69.2% respectively (Table 5). Additionally, we attempted to predict (1) SVR and nonSVR (R+NR), and (2) SVR, R, and NR by DLDA. The accuracy with which patients were classified as SVR and nonSVR, was 56.8% and as SVR, R, and NR was 56.9%.

Genetic variation of IL28B is correlated with the expression of IFN related genes

To examine the relationship between the genetic variation of IL28B and IFN related gene expression, we determined the IL28B polymorphism in 72 patients (Table 6). Patients with the minor genotype of IL28B displayed higher levels of hepatic ISGs expression, whereas patients with the major genotype showed significantly lower expression levels (Figure 2A). In order to further widen our understanding of the above relationship, we significantly identified individual genetic variations in IL28B at the clinical outcome (Figure 2B). We then individually compared the expression level of several IFN-lambda related genes at the clinical outcome with the genetic variation of IL28B. The expression level of interleukin 28A (IL28A), IL28B, interleukin 10 receptor, beta (IL10RB), signal transducer and activator of transcription 1 (STAT1), STAT5A, and tyrosine kinase 2 (TYK2) in IL28B genotype minor allele and major allele did not differ; however, the expression level of STAT5A and IRF9 was significantly higher in IL28B minor allele cases than in major allele (Figure 3A). The expression levels of these nine genes did not significantly differ among the clinical outcomes (NR, R, and SVR) (Table 3). In addition, most genes with expression levels in NR that were higher or lower than in NL, also differed between NR and SVR. Therefore, it is possible that innate immunity in the early period of HCV infection strongly influences IFN reaction.

HCV infection induces the impairment of cell subset number and the function of plasmacytoid dendritic cells (PDC) and natural killer cells [15]. The amount of PDC, which are the most potent producers of antiviral Type-I and III IFN [16], decreased in patients’ peripheral blood [17], however, PDC was trapped in the HCV infected liver tissue. Therapeutic non-responders had increased PDC migration to inflammatory chemokines before therapy, compared with therapeutic responders [18]. This situation resulted in elevated expressions of IFN-related genes in the CH samples and was associated with their inability to eliminate the virus [19].

Inadequate expression of IFN related genes has been associated with several diseases. High expression of ISG can induce a refractory state in IFN therapy [20] and impaired IFN production leads to high risk of HCV-related hepatocarcinogenesis [21]. Lymphocyte IFN signaling was less responsive in patients with breast cancer, melanoma, and gastrointestinal cancer and these defects may represent a common cancer-associated mechanism of immune dysfunction. Alternately, since immunotherapeutic strategies require functional immune activation, such impaired IFN signaling may hinder therapeutic approaches designed to stimulate anti-tumor immunity [22]. In this way, the dysregulation of the IFN system can influence the progression of diseases and decrease curative effects.

### Table 2. Extracted genes related to the clinical outcome with a fold change greater than or equal to 1.5 between two groups (NR/SVR, NR/R) (p<0.05).

| Accession No. | gene                      | symbol     | fold change (NR/SVR) | p-value |
|---------------|---------------------------|------------|----------------------|---------|
| NM_006417.4   | interferon, alpha-inducible protein 44 | IFI44      | 2.13                 | 2.01E-03|
| NM_005322.3   | interferon, alpha-inducible protein 27 | IFI27*     | 2.37                 | 2.01E-03|
| NM_016816.2   | 2’5’-oligoadenylate synthetase 1, 40/46kDa, transcript variant 1 | OAS1       | 2.51                 | 1.36E-02|
| NM_005101.2   | ISG15 ubiquitin-like modifier | ISG15*     | 2.68                 | 1.18E-03|
| NM_002462.2   | myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) | MX1*       | 2.71                 | 1.57E-03|
| NM_005323.3   | interferon, alpha-inducible protein 27 | IFI27*     | 2.33                 | 1.69E-03|
| NM_005101.2   | ISG15 ubiquitin-like modifier | ISG15*     | 2.5                  | 1.11E-03|

Asterisk deposits extracted genes that are common to both SVR and NR and to NR and R.

doi:10.1371/journal.pone.0019799.t002
Table 3. List of genes that had significantly different expression levels in NR and NL (fold change <1/3, 3<, and p<0.05).

| Symbol | NR/NL (fold change) | NR/NL (t-test) | NR/SVR (fold change) | NR/SVR (t-test) |
|--------|---------------------|----------------|----------------------|----------------|
| GADD45B | 0.20 | 1.14E-02 | 1.01 | NS |
| HEV1 | 0.26 | 1.26E-03 | 0.97 | NS |
| BCL3 | 0.26 | 1.84E-02 | 1.02 | NS |
| STAT3 | 0.26 | 5.81E-04 | 0.97 | NS |
| SOCS3 | 0.27 | 7.96E-03 | 0.68 | 2.15E-02 |
| DDX11 | 0.28 | 4.33E-05 | 0.59 | 9.52E-03 |
| TRIM22 | 3.06 | 2.91E-03 | 1.37 | 7.97E-03 |
| ASC | 3.19 | 1.35E-03 | 1.33 | 4.07E-03 |
| UBE2L6 | 3.32 | 1.06E-02 | 1.41 | 1.01E-03 |
| STAT1 | 3.38 | 6.04E-04 | 1.33 | 1.86E-02 |
| ISG20 | 3.64 | 2.42E-04 | 1.42 | 2.37E-03 |
| TRAIL | 3.81 | 2.08E-02 | 0.78 | NS |
| OAS2 | 4.02 | 2.91E-03 | 1.89 | 1.07E-04 |
| IFIT2 | 4.60 | 1.48E-03 | 1.56 | 8.34E-05 |
| BST2(Tetherin) | 5.14 | 8.17E-03 | 1.49 | 5.67E-04 |
| IFI35 | 5.29 | 1.35E-03 | 1.63 | 2.37E-05 |
| HERC5 | 5.32 | 1.16E-03 | 1.68 | 4.07E-05 |
| MX1 | 6.21 | 1.33E-03 | 2.94 | 8.46E-07 |
| HLA-C | 6.49 | 6.34E-04 | 1.21 | NS |
| CCL5(RANTES) | 6.73 | 5.48E-04 | 1.25 | 3.77E-02 |
| HLA-B | 6.84 | 4.91E-04 | 1.22 | NS |
| OAS1 | 7.80 | 5.52E-04 | 2.75 | 1.92E-04 |
| HLA-A | 8.49 | 5.92E-05 | 1.41 | 9.08E-04 |
| B2m | 9.09 | 7.78E-04 | 1.25 | 1.89E-02 |
| IFIT1 | 9.42 | 1.86E-03 | 2.11 | 1.41E-05 |
| OASL | 10.38 | 3.97E-06 | 1.48 | 1.24E-02 |
| IFIT3 | 10.45 | 4.33E-05 | 2.11 | 5.63E-06 |
| CCL10(IP10) | 15.67 | 8.89E-07 | 1.28 | NS |
| IFI44 | 17.00 | 9.40E-05 | 2.22 | 4.83E-06 |
| ISG15 | 21.12 | 1.05E-04 | 2.85 | 3.99E-05 |
| IFI27 | 43.74 | 1.80E-05 | 2.56 | 5.62E-05 |

Genes which participate in IFN production (TLR7, MyD88, IRAK1, and IRF7) did not show any significant difference in their expression level prior to CH combination therapy, and their level at the clinical outcome (Figure 4A and 4B). However, the gene expression pattern of down-stream IFN pathway genes (IFI27, IFI44, ISG15, MX1, and OAS1) was significantly different among SVR, R, and NR (Table 2). IFN is usually up-regulated in HCV infected cells; however in some cases, the mechanism that controls IFN becomes abnormal, and the expression levels of IFN and ISG remain high without any curative effect [23]. The ISG family was generally up-regulated in NR compared to SVR [24–27] and this high expression of ISG related genes was associated with poor response to IFN therapy in previous, as well as in this present study. ISG15 has been linked to innate immune response to viruses and to cellular response to IFN. Although over-expression of ISG15 enhances the antiviral activity of IFN in vitro in acute infection [28], in chronic infection, extended pre-activation of IFN induced genes leads to dysregulation of the IFN system.

CH therapy is still imperfect at present and therefore suitable prediction methods are necessary to avoid adverse effects. Treatment failure using CH combination therapy is associated with up-regulation of a specific set of IFN-responsive genes thereby making it possible to predict non-response to exogenous therapy [29]. Early gene expression during anti-HCV therapy may elucidate important molecular pathways that might be influencing the probability of achieving a virological response [30]. Our study supports this fact by demonstrating that CH and NL differ fundamentally in their innate response to CH combination therapy.

IFN related gene expression suggests novel aspects of HCV pathogenesis, and form the basis for a diagnostic biomarker that can determine early on whether a patient treated with combination therapy is likely to be NR or not. In this respect, what sets our analysis apart is the effect of using DLDA to predict final response with high accuracy in NR and non-NR groups. This prediction showed that the expectation in NR (proportion of actual non-NR versus the predicted number of non-NR) was 93.3% and overall accuracy was 86.1%. In prior report, Dill et al. successfully predicted SVR, but were unable to predict R and NR with high accuracy [31]. In our experiments on the other hand, we predicted NR with high accuracy but were unable to do so for SVR and R. Possible causes for differences between our results and those received by Dill et al. may be (1) the differences in the races of subjects; European patients vs. Japanese patients in our study, (2) the composition of genotype; genotype 1 and 4 vs. genotype 1b in our study, and (3) the difference of the ISG genes extracted.

Genome-wide association studies have described allelic variants near the IL28B gene that are associated with treatment response and with spontaneous clearance of HCV [11–13]. In order to clarify the relationship between IL28B polymorphism and drug response, we compared the expression level of IFN-lambda related gene at the clinical outcome with any genetic variation in IL28B. The expression of hepatic ISG and related genes was strongly associated with treatment response and genetic variation of IL28B [32]. Classification of the patients into SVR and NR revealed that ISG expression was conditionally independent of the IL28B genotype. In CH patients in Europe, the expression pattern of genes induced by IFN more accurately predicts CH combination treatment clinical outcome than polymorphism of IL28B [31]. We observed that curative effect prediction using IFN gene expression pattern resulted in high level of accuracy, however, IFN with IL28B or IFN alone resulted in approximately similar levels of accuracy but were unable to predict R and NR with high accuracy [31]. In our experiments on the other hand, we predicted NR with high accuracy but were unable to do so for SVR and R. Possible causes for differences between our results and those received by Dill et al. may be (1) the differences in the races of subjects; European patients vs. Japanese patients in our study, (2) the composition of genotype; genotype 1 and 4 vs. genotype 1b in our study, and (3) the difference of the ISG genes extracted.
SVR, clinicians could potentially reduce the side effects and costs associated with these regimens and provide a more personalized approach to treating CH patients.

Materials and Methods

Patients and sample preparation
Eighty seven CH patients with HCV genotype 1b in the Department of Gastroenterology at the Ogaki Municipal Hospital were enrolled between 2004 and 2006 (Table 1). Patients with autoimmune hepatitis, alcohol-induced liver injury, and patients positive for hepatitis B virus associated antigen/antibody or anti-human immunodeficiency virus antibody were excluded. None of the patients had received IFN therapy or immunomodulatory therapy prior to enrollment. Five normal liver specimens were obtained by surgical resection. Three of these were obtained from Osaka City University Hospital and were taken from gall bladder cancer, cholangiocarcinoma, and hemangioma patients whose liver tissue were normal based on histological, virological and blood examination of their liver function. The remaining two normal liver samples were obtained from the Liver Transplantation Unit of Kyoto University Hospital.

Patients’ serum HCV RNA was quantified before IFN treatment using Amplicor-HCV Monitor Assay (Roche Molecular Diagnostics Co., Tokyo, Japan). Histological grading and staging of liver biopsy specimens from the CH patients were performed according to the Metavir classification system. Pretreatment blood samples were analyzed to determine the level of aspartate aminotransferase, alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γGTP), white blood cell (WBC), platelets, and hemoglobin. Written informed consent was obtained from all patients or their guardians and provided to the Ethics Committee of the Graduate School of Kyoto University, Osaka City University and Ogaki Municipal Hospital, who approved this study in accordance with the Helsinki Declaration.

Treatment protocol
For all enrolled patients, treatment with PegIFN-α-2b (Schering-Plough Corporation, Kenilworth, NJ, USA) and ribavirin (Schering-Plough) was initiated at the beginning of the 1st week and lasted for 48 weeks. PegIFN was administrated at a dose of 1.5 mg kg/week and ribavirin was administrated at the dose recommended by the manufacturer.

Definition of drug response to therapy
The patients were classified into the following three groups at the completion of follow-up period (24 weeks): (1) sustained virological responder (SVR): a patient who was negative for serum HCV RNA during the 24 weeks following the completion of the

Table 4. Characteristics of the training and validation set.

|                  | non NR (SVR+R) group | non NR (SVR+R) group | NR group | NR group |
|------------------|----------------------|----------------------|----------|----------|
|                  | average (training set) | average (validation set) | p-value | average (training set) | average (validation set) | p-value |
| No.              | 32                   | 32                   | 12       | 11       |
| Age              | 59.3                 | 57.1                 | 0.38     | 60.6     | 61.7     | 0.74     |
| HCV RNA (×10⁶ IU/ml) | 1.77               | 2.08                 | 0.48     | 1.51     | 1.52     | 0.97     |
| AST (IU/L)       | 44.6                 | 65.3                 | 0.06     | 55.3     | 56.9     | 0.89     |
| ALT (IU/L)       | 50                   | 87.3                 | 0.05     | 67.7     | 66.8     | 0.96     |
| WBC (×10⁹/mm³)   | 5220                 | 5480                 | 0.57     | 4610     | 4860     | 0.6      |
| Platelet (×10⁹/mm³) | 15.8               | 17.6                 | 0.15     | 15       | 15.2     | 0.95     |
| Total bilirubin (mg/dl) | 0.71               | 0.69                 | 0.78     | 0.68     | 0.68     | 0.92     |
| weight           | 58.1                 | 59.2                 | 0.67     | 57       | 53.8     | 0.28     |
| ALP (IU/L)       | 251                  | 249                  | 0.92     | 298      | 326      | 0.64     |
| γGTP (IU/L)      | 48                   | 57.4                 | 0.54     | 73.3     | 73.8     | 0.98     |
| Hemoglobin (g/dl) | 13.9                 | 14.1                 | 0.53     | 13.7     | 13.5     | 0.78     |
| Albumin (g/dl)   | 4.15                 | 4.21                 | 0.41     | 4.11     | 3.98     | 0.52     |

Table 5. Quality of NR-prediction by DLDA.

|                  | Predicted          |     |     |
|------------------|--------------------|-----|-----|
|                  | NR                 | nonNR(SVR+R) | Total |
| Diagnosed        | 9                  | 2    | 11   |
|                  | 4                  | 28   | 32   |
| Total            | 13                 | 30   | 43   |

doi:10.1371/journal.pone.0019799.t005

Table 6. Result of the IL28B polymorphism (rs8099917).

| rs8099917 | TT | TG | GG |
|-----------|----|----|----|
| outcome   | NR | 7  | 12 | 1  |
|           | Relapse | 18 | 3  | 0  |
|           | SVR    | 30 | 1  | 0  |
| Total     | 55     | 16 | 1  |

doi:10.1371/journal.pone.0019799.t006
Figure 2. The relationship among the expression of IFN-related genes, IL28B polymorphism and clinical outcome. (A) The relationship between expression of ISG and five related genes (MX1, OAS1, ISG15, IFI27, and IFI44) in the liver of CH patients and IL28B with the major (TT) or minor (TG or GG) genotype (rs8099917) is shown. The p-value of the relationship between gene expression level and IL28B genotype is also depicted. (B) The relationship among the expression level of the above five genes, clinical outcome, and IL28 genotype in individual cases. Red square, green circle, and blue rectangle represent TT, TG, and GG in IL28B genotype, respectively. The p value was calculated from a linear regression employing outcome as an explanatory variable (in which SVR, R and NR are encoded to 0, 1 and 2 respectively) and expression level as the response variable. We tested the null hypothesis that the coefficient of the outcome is 0. Summary table of the p-value is also shown. NS shows no significant difference. doi:10.1371/journal.pone.0019799.g002

Figure 3. The relationship among the expression of IFN lambda-related genes, IL28B polymorphism and clinical outcome. (A) The relationship between the expression level of IFN lambda related genes (TYK2, STAT5A, STAT1, IL10RB, IL29, IL28A, IL28B, JAK1, and IRF9) in the liver of CH patients and IL28B with genotype. The p-value of the relationship between gene expression level and IL28B genotype is also presented. (B) The relationship among IFN lambda related genes, clinical outcome, and IL28 genotype in individual cases. Summary table of the p-value is also shown. NS was not significantly different. doi:10.1371/journal.pone.0019799.g003
combination therapy; (2) relapse (R): a patient whose serum HCV RNA was negative by the end of the combination therapy but reappeared during the 24 week observation period; and (3) non-responder (NR): a patient who was positive for serum HCV RNA during the entire course of the combination therapy (Figure 5). No patients were withdrawn from the study due to side effects or any other reason.

RNA preparation and real-time qPCR

Total RNA from tissue samples was prepared using a mirVana miRNA extraction Kit (Ambion, Austin, TX, USA) according to the manufacturer’s instruction. cDNA was synthesized by Transcriptor High Fidelity cDNA synthesis Kit (Roche, Basel, Switzerland). Total RNA (2 μg) in 11 μl of nuclease free water was added to 1 μl of 50 mM random hexamer and denatured for 10 min at 65°C. The denatured RNA mixture was added to 4 μl of 5x reverse transcriptase buffer, 2 μl of 10 mM dNTP, 0.5 μl of 40 U/ml RNase inhibitor, and 0.5 μl of reverse transcriptase (FastStart Universal SYBR Green Master (Roche) in a total volume of 20 μl. cDNA synthesis was performed for 30 min at 50°C, and enzyme denaturation for 5 min at 85°C. Chromo 4 detector (Bio-Rad, Hercules, CA, USA) was used to detect mRNA expression. Assays were performed in triplicate, and the expression levels of target genes were normalized to that of the β-actin gene, as quantified using real-time qPCR as internal controls. Nucleotide sequences of primers were as follows: IFI27 (sense) 5’-ctaggccacggataaaacc-3’, IFI27 (anti-sense) 5’-gactgcagagtagc-cacaag-3’, IFI44 (sense) 5’-gcatgtaacgcatcaggctt-3’, IFI44 (anti-sense) 5’-ccacaccagctttaccaac-3’, ISG15 (sense) 5’-ctttgccagta-caggagctt-3’, ISG15 (anti-sense) 5’-gccctgttattcctcacca-3’, MX1 (sense) 5’-aaacatcgtgctgacacctg-3’, MX1 (anti-sense) 5’-gtgagagctgctgtaag-3’, OAS1 (sense) 5’-gtggtccagccgctgtctgtc-3’, OAS1 (anti-sense) 5’-actagggcttgagcctt-3’, and β-actin (sense) 5’-ccactgcccagttgagc-3’, β-actin (anti-sense) 5’-ttctgcaattgtgagcatc-3’.

Figure 4. The relationship between the expression level of genes which participate in IFN production (TLR7, MyD88, IRAK1, and IFR7) in the liver of CH patients and IL28B genotype. (A) The relationship between IFN early response genes and clinical outcome is shown. A summary table of the p-value is also presented. NS shows no significant difference. (B) The relationship between IFN early response genes and IL28B genotype is shown. The p-value is also presented. doi:10.1371/journal.pone.0019799.g004

Table 7. Quality of NR-prediction by DLDA with IFN related gene and IL28B polymorphism A.IFN+IL28B.

| Predicted | NR | nonNR | Total |
|-----------|----|-------|-------|
| Diagnosed |    |       |       |
| NR        | 7  | 2     | 9     |
| nonNR     | 4  | 23    | 27    |
| Total     | 11 | 25    | 36    |

doi:10.1371/journal.pone.0019799.t007

Table 8. Quality of NR-prediction by DLDA with IFN related gene only.

| Predicted | NR | nonNR | Total |
|-----------|----|-------|-------|
| Diagnosed |    |       |       |
| NR        | 8  | 1     | 9     |
| nonNR     | 5  | 22    | 27    |
| Total     | 13 | 23    | 36    |

doi:10.1371/journal.pone.0019799.t008
cDNA microarray
RNA was amplified and biotinylated using the MessageAmp-Biotin Enhanced Kit (Ambion). DNA oligonucleotide probes were synthesized onto a DNA microarray chip called Genopal (Mitsubishi Rayon) in order to detect the 237 genes (200 genes on Chip1 and 37 genes on Chip2) related to the innate immune response. Hybridization was carried out overnight at 65 °C using Genopal in an hybridization buffer [0.12 M Tris-HCl/0.12 M NaCl/0.05% Tween-20]. After hybridization, Genopal was washed with hybridization buffer twice at 65 °C for 20 min followed by washing in 0.12 M Tris-HCl/0.12 M NaCl at 65 °C for 10 min. Genopal was then labeled with streptavidin-Cy5 (GE Healthcare Bioscience, Tokyo, Japan). The fluorescent labeled-Genopal was washed for 5 min four times with hybridization buffer at RT and scanned at multiple exposure times ranging from 0 to 40s by DNA microarray reader (Yokogawa Electric Co., Tokyo, Japan). Intensity values with the best exposure condition for each spot were selected. The data presented here have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE20119: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xlmbxyyumcwkeba&acc=GSE20119. All data are MIAME compliant, and are also registered with GEO.

Statistical analysis
To identify the genes that varied significantly among NR, R, SVR and NL groups, one-way ANOVA and Turkey’s post hoc tests were used to assess each of the 237 IFN related-genes on the arrays. Benjamini-Hochberg correction for multiple hypotheses testing was applied to all tests. P values <0.05 were considered statistically significant.

Method of predicting prognosis
The patients were randomly divided into two groups: one was used as a TS and the other as VS to calculate the prediction discriminant. A prognosis signature (PS) was defined in terms of the expression levels of the six genes that differed significantly between NR and non-NR groups using post hoc analysis (IFIT2, IFI44, interferon-induced protein with tetratricopeptide repeats 3 (IFT3), ISG15, MX1, OAS1). A prognosis predictor (PP) was computed by applying a diagonal linear DDLDA to the TS [33] and then using it to predict the prognoses of the VS. The predicted and actual prognoses of VS patients were compared to obtain the following five measures of prognosis prediction performance: accuracy (proportion of correctly predicted prognoses), sensitivity (proportion of correctly predicted non-NR), specificity (proportion of correctly predicted NR), PPV (proportion of actual non-NR versus predicted non-NR) and NPV (proportion of actual NR versus predicted NR).

Genetic Variation of IL28B Polymorphism
Genotypes rs8099917 was determined in 72 out of 87 patients by Taqman SNP assays (Applied Biosystems) using a pre-designed and functionally tested probe (ABI assay ID (C_11710096_10). The experiment was carried out according to the manufacturer’s instruction.

Supporting Information
Figure S1 Real-time qPCR validation of the five IFN related genes. Each column represents the relative amount of mRNAs normalized to expression level of β-actin. The data shown are means±SD of three independent experiments. Asterisk was indicated to the significant difference at p<0.05. (TIF)

Acknowledgments
The authors would like to thank Akihiro Tamori and Shouji Kubo of Osaka City University, for providing the liver samples taken from healthy patients.

Author Contributions
Conceived and designed the experiments: KS YM. Performed the experiments: KO SM T. Kawaguchi YM. Analyzed the data: T. Kawaguchi MT MK. Contributed reagents/materials/analysis tools: HT KU T. Kawaguchi YM. Performed the experiments: KO SM T. Kawaguchi YM. Wrote the paper: HT KU T. Kawaguchi FM TF YM.

References
1. Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23–61.
2. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, et al. (2006) Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale longitudinal study in a single center. Internatology 49: 82–90.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
4. Accola MA, Huang B, Al Masri A, McNiven MA (2002) The antiviral dynamin family member, maxiA, tubulates lipids and localizes to the smooth endoplasmic reticulum. J Biol Chem 277: 21829–21835.
5. Malathi K, Dong B, Gale M, Jr., Silverman RH (2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448: 816–819.
6. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin...
combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitution in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46: 403–410.

7. Enomoto N, Sakuma I, Asahima Y, Kurouki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77–81.

8. Bondini S, Younossi ZM (2006) Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 52: 135–143.

9. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, et al. (2007) Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 13: 1100–1108.

10. Murakami V, Tanaka M, Toyoda H, Hayashi K, Kuroda M, et al. (2010) Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 3: 48.

11. Tanaka Y, Nishida N, Sugiyama M, Kurouki M, Matsuura K, et al. (2010) Genome-wide association of IL28B with response topegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.

12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100–1104.

13. Ge D, Fellay J, Thompson AJ, Simion JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.

14. Szabo G, Chang S, Dolganovic A (2007) Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology 45: 1279–1290.

15. Coury SJ, Millochivitch KA, Yenkers NL, Rodriguez GB, Bernstein HB, et al. (2009) Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in tissucn human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J Virol 83: 11175–11187.

16. Pulendran B, Tang H, Denning TL (2010) Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in chronic hepatitis C infection. Gastroenterology 138: 1123–1133 e1121-1123.

17. Chen L, Borozan I, Sun J, Guindi M, Fischer S, et al. (2010) Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138: 1130–1139 e1121-1123.

18. Okumura A, Lu G, Pitha-Rowe I, Pitha PM (2006) Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103: 1440–1445.

19. Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, et al. (2007) Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 150: 116–121.

20. Younossi ZM, Barberova A, Alfrindy A, Collantes R, Stepanova M, et al. (2009) Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 49: 763–774.

21. Dill MT, Duong FH, Voge JE, Ribets I, Bochud PV, et al. (2011) Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. Gastroenterology.

22. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 107: 5034–5039.

23. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Debas FM, et al. (2009) Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 106: 9010–9015.

24. Ge D, Fellay J, Thompson AJ, Simion JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.